Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

Detected CMS Systems:

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. Hosting Providers
  13. CDN Services

We began analyzing https://journals.lww.com/melanomaresearch/abstract/2012/08000/a_randomized_phase_ii_study_of_cilengitide__emd.2.aspx, but it redirected us to https://journals.lww.com/melanomaresearch/abstract/2012/08000/a_randomized_phase_ii_study_of_cilengitide__emd.2.aspx. The analysis below is for the second page.

Title[redir]:
Melanoma Research
Description:
nical efficacy of cilengitide. Patients with stage IV or unresectable stage III melanoma who were either chemonaive or who had previously received one systemic therapy were enrolled. Patients were randomly assigned to either 500 or 2000 mg of cilengitide administered intravenously twice weekly. The primary aim of this study was to determine the progression-free survival rate at 8 weeks. Tumor samples and blood samples were collected for pharmacodynamic and pharmacokinetic studies. Twenty-nine patients were enrolled, of whom 26 were treated (14 at 500 mg and 12 at 2000 mg). Among those treated, only three were progression free at 8 weeks: two in the 500 mg arm and one in the 2000 mg arm. One patient in the 2000 mg arm showed a prolonged partial response after an initial 28% enlargement of her target lesions. The treatment was well tolerated without clinically significant adverse events. The sole responder and one of two patients with stable disease had no αvβ3 expression at baseline. Overall, αvβ3 expression was decreased by day 8 of the treatment (P=0.05). Cilengitide was well tolerated by patients in both the treatment arms but had minimal clinical efficacy as a single-agent therapy for metastatic melanoma, and the efficacy was not related to baseline αvβ3 expression....

Matching Content Categories {📚}

  • Health & Fitness
  • Science
  • Education

Content Management System {📝}

What CMS is doi.org built with?


Doi.org uses MYBB.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌍 Impressive Traffic: 500k - 1M visitors per month


Based on our best estimate, this website will receive around 600,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We see no obvious way the site makes money.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Doi.org could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

journal, patients, melanoma, αvβ, cilengitide, issue, access, subscribe, alerts, submit, articles, authors, abstract, clinical, metastatic, efficacy, arm, treatment, expression, log, register, issues, research, randomized, phase, study, emd, buy, cells, survival, stage, therapy, enrolled, weeks, samples, treated, tolerated, baseline, text, subscribers, request, browse, content, service, privacy, policy, manuscript, logo, advanced, search,

Topics {✒️}

progression-free survival rate journal authors submit full text access prolonged partial response artificial intelligence training single-agent therapy cilengitide administered intravenously service request 800-638-3030 minimal clinical efficacy register subscribe individual subscribers log baseline αvβ3 expression journal tables progression free clinical research metastatic melanoma etoc alerts melanoma cells stage iv website subscribe center submit αvβ3 expression journal systemic therapy clinical efficacy integrins αvβ3 αvβ3 promotes selective inhibitor endothelial cells previously received randomly assigned primary aim blood samples pharmacokinetic studies 500 mg arm 2000 mg arm initial 28% enlargement target lesions sole responder stable disease email inbox rights reserved data mining issue tumor samples treatment arms authors content survival study

Questions {❓}

  • Not a Subscriber?

External Links {🔗}(56)

Analytics and Tracking {📊}

  • Comscore
  • Google Analytics
  • Google Tag Manager

Libraries {📚}

  • Bootstrap
  • FontAwesome
  • jQuery
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Cookielaw
  • Jsdelivr
  • Scite
  • Wolterskluwer

5.34s.